Biolase (BIOL) Misses Q2 EPS by 27c

Biolase (NASDAQ: BIOL) reported Q2 EPS of ($0.91), $0.27 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.63 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• Alibaba (BABA) Misses Q2 EPS by 220c